
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is projected to experience significant growth, with WAKIX sales expected to rise from approximately $160 million in 2020 to over $700 million by 2024, driven by its safety and convenience advantages. The company is well-positioned for further expansion through its robust orphan drug pipeline, which includes promising candidates for various neurological conditions, potentially leading to new drug applications and market differentiation. Additionally, the positive results from the dosing optimization study for pitolisant-GR indicate improved patient adherence due to the elimination of dose titration, thereby enhancing long-term value and potentially extending market exclusivity through 2044.
Bears say
The financial outlook for Harmony Biosciences Holdings Inc. appears negative due to several key risks that may hinder revenue growth from its primary product, WAKIX. The potential entry of new competitors and earlier-than-expected competition from generic versions of pitolisant could significantly impact market share and pricing power. Additionally, the uncertainty surrounding the success of ongoing clinical trials for various drug candidates raises concerns about the company's ability to expand its product line and address unmet medical needs, further complicating its growth prospects.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares